FDA Approves Breakthrough HIV Drug

Ulrich baumgarten/Getty

WASHINGTON, 2025-06-18

A Breakthrough in HIV Prevention

The FDA has approved an injectable drug to prevent HIV transmission, offering a promising new tool in the fight against AIDS, but its arrival coincides with concerning cuts to global AIDS initiatives.

• The FDA approved Yeztugo (lenacapavir), an injectable drug for HIV prevention.
• Clinical trials showed Yeztugo was highly effective in preventing HIV infection.
• The approval comes amid funding cuts to global AIDS programs.

On Wednesday,the Food and Drug Administration approved Yeztugo (lenacapavir),an injectable medication,to help prevent the transmission of HIV,according to its manufacturer,Gilead Sciences. This drug is poised to become a vital tool in HIV prevention.

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in a press release. He added that Yeztugo “offers a very real opportunity to help end the HIV epidemic.”

Clinical trials demonstrated lenacapavir’s stunning efficacy as pre-exposure prophylaxis, or PrEP, preventing infection in 100 percent of participants in one trial and 99.9 percent in another.

challenges Amidst Progress

Though, the approval of Yeztugo arrives at a challenging time, coinciding with critically important cuts to global AIDS programs during the Trump administration.

Did you know?-PrEP, or pre-exposure prophylaxis, involves taking medications daily or via injection to prevent HIV infection. It is highly effective when taken as prescribed.

These cuts include reductions to the united States Agency for International Development (USAID),an agency focused on fighting diseases like AIDS worldwide,and significant reductions to PEPFAR,the U.S. President’s Emergency Plan for AIDS Relief, a program that has saved an estimated 26 million lives since its start in 2003. Furthermore, several HIV prevention studies have been shut down.

Such as, the MATRIX study, a $125 million project funded by USAID, was designed to evaluate new HIV prevention products for women. The study was abruptly ended mid-data collection due to a January executive order. Dr.Catherine Chappell, an OB-GYN, who helped lead the trial, expressed concern that dropping the study could have “irreparably damaged” the relationship with the community. “It is just entirely unethical,” she stated.

Reader question:-What are the potential long-term consequences of cutting funding for global AIDS programs, especially in light of new preventative medications? Share your thoughts in the comments.

Researchers at USAID had also planned additional clinical trials for lenacapavir. A former USAID analyst said, “All of that’s just been cut off.”

In the wake of decades of research, science delivered the most effective preventative HIV drugs the world has ever seen, but the U.S. is abandoning efforts to share them with those most in need.

As Mitchell Warren, the executive director of the nonprofit AIDS Vaccine Advocacy Coalition, stated, “We’re on the precipice of now being able to deliver the greatest prevention option we’ve had in 44 years of this epidemic. And it’s as if that opportunity is being snatched out of our hands by the policies of the last five months.”

The Impact of Funding Cuts on U.S. HIV prevention Programs

The approval of Yeztugo (lenacapavir) for HIV prevention, as highlighted in the previous section, represents a important leap forward. Despite this progress, the potential of this and other preventative measures is threatened by concerning cuts to HIV prevention funding, primarily within the United States. This section will explore the immediate and future implications of these cuts,focusing on how they undermine the progress made in combating the HIV/AIDS epidemic within the U.S.

Presidential budget proposals for 2026 have proposed significant cuts to various HIV programs. As an example, one proposal suggests consolidating funding into a single program, but at a level $77 million less than what current individual programs receive [[1]]. The Centers for Disease Control and Prevention (CDC), which manages 90% of all federal HIV prevention funding, faces cuts that could total billions of dollars [[3]].This woudl seriously impact the CDC’s capacity to support health departments across the nation.

These cuts jeopardize critical programs that support health departments, community-based organizations, and vital surveillance systems. The elimination of these programs would lead to a reduction in essential resources.

• Impact on Prevention Efforts: Funding reductions could lead to the cessation of HIV prevention activities in numerous states [[2]].programs providing testing, counseling, and access to PrEP, including the newly approved injectable lenacapavir, might potentially be scaled back or eliminated.
• Strain on Resources: With diminished federal support, state and local health departments will struggle to maintain prevention initiatives. This includes efforts to reach high-risk populations, such as people who inject drugs, men who have sex with men, and people of color.
• Surveillance and Data Collection: Funding cuts also risk disrupting HIV surveillance programs. These programs are crucial for monitoring the prevalence of HIV and understanding the efficacy of interventions. Reduced surveillance capabilities can impede the ability to respond to outbreaks and tailor prevention strategies effectively.

The proposed cuts also reflect a shift in budgetary priorities, with some proposals consolidating funding or redirecting resources toward other public health concerns, like the opioid epidemic and STI and TB programs [[1]]. While addressing these challenges is important, reallocating funds from established HIV prevention programs could undermine years of progress and increase the risk of new infections.

One of the most concerning aspects of these budget proposals is the potential impact on community-level organizations,which are essential in providing targeted prevention programs. Specifically, these efforts are the backbone of HIV prevention. These organizations provide testing, counseling, and access to care in marginalized communities.

Consider this: Without the ongoing support of federal funding, community-based organizations may be forced to scale back programs or close entirely, leaving many at higher risk of infection without access to vital services.

The convergence of scientific breakthroughs, like lenacapavir, and funding cuts paints a troubling picture. The United States appears to be limiting the distribution of prevention efforts to at-risk individuals.This also includes essential preventative approaches such as widespread testing, access to prep, and support for those living with HIV.

The potential consequences include increased HIV infection rates. This would reverse the decline that has been observed over the past decade, and the exacerbation of health disparities.

What Can Be done? Strategies for Action

To mitigate the adverse impacts of these funding cuts, a multi-faceted approach is required:

1. Advocate for Increased Funding: Organizations and individuals can work together to urge Congress to reject these budget proposals and increase funding for HIV prevention programs.
2. Support Community-Based Organizations: donate to local organizations, volunteer time, and help amplify the work done by community leaders.
3. Raise Awareness: Advocate for the importance of HIV prevention and treatment. Educating the public about the benefits of PrEP and ongoing access to care can create a supportive surroundings.

These actions would serve to ensure that the latest scientific advances in HIV prevention are accessible to all and prevent the erosion of decades of progress in the fight against AIDS.